Literature DB >> 19414706

Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability.

Aaron L Goldman1, Lukas Pezawas, Venkata S Mattay, Bruce Fischl, Beth A Verchinski, Qiang Chen, Daniel R Weinberger, Andreas Meyer-Lindenberg.   

Abstract

CONTEXT: Schizophrenia is a brain disorder with predominantly genetic risk factors, and previous research has identified heritable cortical and subcortical reductions in local brain volume. To our knowledge, cortical thickness, a measure of particular interest in schizophrenia, has not previously been evaluated in terms of its heritability in relationship to risk for schizophrenia.
OBJECTIVE: To quantify the distribution and heritability of cortical thickness changes in schizophrenia.
DESIGN: We analyzed a large sample of normal controls, affected patients, and unaffected siblings using a surface-based approach. Cortical thickness was compared between diagnosis groups on a surfacewide node-by-node basis. Heritability related to disease risk was assessed in regions derived from an automated cortical parcellation algorithm by calculating the Risch lambda.
SETTING: Research hospital. PARTICIPANTS: One hundred ninety-six normal controls, 115 affected patients with schizophrenia, and 192 unaffected siblings. MAIN OUTCOME MEASURE: Regional cortical thickness.
RESULTS: Node-by-node mapping statistics revealed widespread thickness reductions in the patient group, most pronouncedly in the frontal lobe and temporal cortex. Unaffected siblings did not significantly differ from normal controls at the chosen conservative threshold. Risch lambda analysis revealed widespread evidence for heritability for cortical thickness reductions throughout the brain.
CONCLUSIONS: To our knowledge, the present study provides the first evidence of broadly distributed and heritable reductions of cortical thickness alterations in schizophrenia. However, since only trend-level reductions of thickness were observed in siblings, cortical thickness per se (at least as measured by this approach) is not a strong intermediate phenotype for schizophrenia.

Entities:  

Mesh:

Year:  2009        PMID: 19414706      PMCID: PMC2719488          DOI: 10.1001/archgenpsychiatry.2009.24

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  65 in total

1.  Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex.

Authors:  B Fischl; A Liu; A M Dale
Journal:  IEEE Trans Med Imaging       Date:  2001-01       Impact factor: 10.048

Review 2.  Structural neuroimaging in schizophrenia. An integrative view of neuromorphology.

Authors:  F A Henn; D F Braus
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

3.  High-resolution intersubject averaging and a coordinate system for the cortical surface.

Authors:  B Fischl; M I Sereno; R B Tootell; A M Dale
Journal:  Hum Brain Mapp       Date:  1999       Impact factor: 5.038

Review 4.  Catching up on schizophrenia: natural history and neurobiology.

Authors:  D A Lewis; J A Lieberman
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

5.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.

Authors:  Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany
Journal:  Neuroimage       Date:  2006-03-10       Impact factor: 6.556

6.  Meta-analysis of regional brain volumes in schizophrenia.

Authors:  I C Wright; S Rabe-Hesketh; P W Woodruff; A S David; R M Murray; E T Bullmore
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

7.  Measuring the thickness of the human cerebral cortex from magnetic resonance images.

Authors:  B Fischl; A M Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

8.  Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study.

Authors:  C S Carter; A W MacDonald; L L Ross; V A Stenger
Journal:  Am J Psychiatry       Date:  2001-09       Impact factor: 18.112

9.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.

Authors:  M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

10.  Structural brain abnormalities in patients with schizophrenia and their healthy siblings.

Authors:  W G Staal; H E Hulshoff Pol; H G Schnack; M L Hoogendoorn; K Jellema; R S Kahn
Journal:  Am J Psychiatry       Date:  2000-03       Impact factor: 18.112

View more
  104 in total

1.  Cortical thickness and surface area in neonates at high risk for schizophrenia.

Authors:  Gang Li; Li Wang; Feng Shi; Amanda E Lyall; Mihye Ahn; Ziwen Peng; Hongtu Zhu; Weili Lin; John H Gilmore; Dinggang Shen
Journal:  Brain Struct Funct       Date:  2014-11-02       Impact factor: 3.270

2.  Evidence from structural and diffusion tensor imaging for frontotemporal deficits in psychometric schizotypy.

Authors:  Pamela DeRosse; George C Nitzburg; Toshikazu Ikuta; Bart D Peters; Anil K Malhotra; Philip R Szeszko
Journal:  Schizophr Bull       Date:  2014-11-11       Impact factor: 9.306

3.  The National Alliance for Medical Image Computing, a roadmap initiative to build a free and open source software infrastructure for translational research in medical image analysis.

Authors:  Tina Kapur; Steve Pieper; Ross Whitaker; Stephen Aylward; Marianna Jakab; Will Schroeder; Ron Kikinis
Journal:  J Am Med Inform Assoc       Date:  2011-11-10       Impact factor: 4.497

4.  Dissociable morphometric differences of the inferior parietal lobule in schizophrenia.

Authors:  Lena Palaniyappan; Peter F Liddle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-28       Impact factor: 5.270

5.  Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults.

Authors:  Elizabeth C Leritz; David H Salat; Victoria J Williams; David M Schnyer; James L Rudolph; Lewis Lipsitz; Bruce Fischl; Regina E McGlinchey; William P Milberg
Journal:  Neuroimage       Date:  2010-10-28       Impact factor: 6.556

Review 6.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

7.  Cortical thickness of neural substrates supporting cognitive empathy in individuals with schizophrenia.

Authors:  Suena H Massey; Daniel Stern; Eva C Alden; Julie E Petersen; Derin J Cobia; Lei Wang; John G Csernansky; Matthew J Smith
Journal:  Schizophr Res       Date:  2016-09-21       Impact factor: 4.939

8.  Relationship between prefrontal gray matter volumes and working memory performance in schizophrenia: a family study.

Authors:  Vina M Goghari; Angus W Macdonald; Scott R Sponheim
Journal:  Schizophr Res       Date:  2014-02-13       Impact factor: 4.939

9.  Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans.

Authors:  Kevin F Casey; Mariya V Cherkasova; Kevin Larcher; Alan C Evans; Glen B Baker; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

10.  Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies.

Authors:  Anderson M Winkler; Peter Kochunov; John Blangero; Laura Almasy; Karl Zilles; Peter T Fox; Ravindranath Duggirala; David C Glahn
Journal:  Neuroimage       Date:  2009-12-16       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.